Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 6, 2024Alzheimer s Research & TherapyOpen Access

Clinical application of plasma P-tau217 to assess eligibility for amyloid-lowering immunotherapy in memory clinic patients with early Alzheimer’s disease

View Full Paper
Ask AI
Bookmark
Share

Authors

MHMatthew D. HoweKBKarysa BrittonHJHannah E. Joyce

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Howe et al. (2024) studied this question.

synapsesocial.com/papers/68e61294b6db6435875a563ehttps://doi.org/10.1186/s13195-024-01521-9
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lecanemab: Appropriate Use Recommendations2023 · 915 citations
  2. 2Association of Plasma and Cerebrospinal Fluid Alzheimer Disease Biomarkers With Race and the Role of Genetic Ancestry, Vascular Comorbidities, and Neighborhood Factors2022 · 96 citations
  3. 3Racial disparities and temporal trends in dementia misdiagnosis risk in the United States2019 · 177 citations
  4. 4Aducanumab: Appropriate Use Recommendations Update2022 · 197 citations
  5. 5A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases2023 · 226 citations